How CAR T Cells Can Change the Treatment Landscape for Non-Hodgkin Lymphoma

David Maloney, MD, PhD, medical director, Cellular Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Research Center, discusses the results of the ZUMA trial and how chimeric antigen receptor CAR T-cell therapy is changing the treatment landscape for non-Hodgkin lymphoma.

Read the full article here

Related Articles